Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer
Oncocyte Corporation (Nasdaq: OCX) announced the peer-reviewed publication of a study utilizing DetermaIO™ in the Phase II AtezoTRIBE clinical trial for metastatic colorectal cancer (mCRC). Published in Clinical Cancer Research, the study indicates that DetermaIO can identify patients likely to benefit from ICI therapy more effectively than current biomarkers. Key findings include improved progression-free survival for DetermaIO positive patients, particularly in the pMMR population. The conclusion points towards a significant shift in understanding tumor microenvironments in mCRC, highlighting DetermaIO's role in identifying patients not recognized by existing methods.
- DetermaIO identifies more responders to ICI therapy than standard biomarkers.
- DetermaIO positive patients showed better outcomes in progression-free survival regardless of MMR status.
- DetermaIO reveals a unique subset of patients in the pMMR group not identified by other biomarkers.
- None.
IRVINE, Calif., April 07, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic company, today announces the peer-reviewed publication of the results of a study applying DetermaIO™ to samples collected from the randomized Phase II AtezoTRIBE clinical trial in metastatic colorectal cancer (mCRC). The results were published in Clinical Cancer Research and showed the utility of DetermaIO in potentially identifying more responders to ICI therapy than current standard of care biomarkers.
Highlights of the peer-reviewed publication include:
- In the overall population (n=122), DetermaIO positive patients achieved better outcomes in terms of progression-free survival from the addition of atezolizumab among mCRC patients than DetermaIO negative patients, regardless of MMR status.
- A similar trend was observed in the pMMR population (n=110) that does not currently qualify for ICI therapy in mCRC.
- In the pMMR group treated with ICI addition to chemo (N=69), patients that had a very high DetermaIO had a significantly improved progression-free survival (HR=0.19
95% CI: 0.09 - 0.40). Overlap between DetermaIO positive, dMMR, and TMB is limited, demonstrating DetermaIO identifies a unique subset of patients not identified by these biomarkers.
The authors conclude, “Our study demonstrates that the gene expression profiling through the DetermaIO of mCRC would mark a fundamental paradigm shift in the characterization of tumor immune microenvironment of mCRC, by providing the opportunity to identify an immune-enriched tumor microenvironment among pMMR tumors that do not currently qualify for ICI therapy.”
About Oncocyte
Oncocyte is a precision diagnostics company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. VitaGraft™ is a blood-based solid organ transplantation monitoring test, and pipeline test DetermaCNI™ is blood-based monitoring tool for monitoring therapeutic efficacy.
DetermaIO™, DetermaCNI™, and VitaGraft™ are trademarks of Oncocyte Corporation
Investor Contact
Jesse Arno
(949) 409-6770
jarno@oncocyte.com
FAQ
What are the results of Oncocyte's DetermaIO study published in April 2023?
How does DetermaIO impact progression-free survival in mCRC?
What is the significance of the DetermaIO results for pMMR patients?
Where was the DetermaIO study published?
